

Protection against HSV-2 is added benefit of tenofovir

July 2 2014



(HealthDay)—Tenofovir for HIV-1 preexposure prophylaxis (PrEP) provides the added benefit of protection against herpes simplex virus type 2 (HSV-2) acquisition, according to a study published in the July 1 issue of the *Annals of Internal Medicine*.

Connie Celum, M.D., M.P.H., from the University of Washington in Seattle, and colleagues conducted a study among heterosexual men and women in Kenya and Uganda who were seronegative for HIV-1 and HSV-2, but at high risk for HIV-1 acquisition due to having an infected partner. Participants were randomized to receive daily oral PrEP with antiretroviral tenofovir disoproxil fumarate (TDF) alone or in combination with emtricitabine (FTC-TDF).

The researchers found that 131 participants seroconverted to HSV-2 (79 of 1,041 assigned to tenofovir or FTC-TDF PrEP [HSV-2 incidence, 5.6



per 100 person-years] versus 52 of 481 assigned to placebo [HSV-2 incidence, 7.7 per 100 person-years]). With daily oral PrEP, the hazard ratio (HR) for HSV-2 acquisition was 0.70 (P = 0.047) compared with placebo, with an absolute risk reduction of 2.1 per 100 person-years. The HR for PrEP was 0.67 (P = 0.038) among the 1,044 participants with HSV-2-infected partners, compared to placebo, with an absolute risk reduction of 3.1 per 100 person-years.

"Modest protection against HSV-2 is an added benefit of HIV-1 prevention with oral tenofovir-based PrEP," the authors write.

More information: <u>Full Text (subscription or payment may be required)</u>

Copyright © 2014 HealthDay. All rights reserved.

Citation: Protection against HSV-2 is added benefit of tenofovir (2014, July 2) retrieved 2 February 2024 from https://medicalxpress.com/news/2014-07-hsv-added-benefit-tenofovir.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.